Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

• Published in: Leukemia Vol. 35; no. 6; pp. 1563 - 1570
• Main Authors: Zhang, Cheng, Wang, Xiao-Qi, Zhang, Rong-Li, Liu, Fang, Wang, Yi, Yan, Zhi-Ling, Song, Yong-Ping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group 01.06.2021; Nature Publishing Group UK
• Subjects: Acute lymphoblastic leukemia; Acute lymphocytic leukemia; Antigen receptors, T cell; Antigens; Cancer; Care and treatment; CD19 antigen; Cell therapy; Cellular therapy; Chimeric antigen receptors; Confidence intervals; Cytokines; Development and progression; Graft-versus-host reaction; Health aspects; Leukemia; Lymphatic leukemia; Lymphocytes; Lymphocytes B; Lymphocytes T; Methods; Neurotoxicity; Oncology, Experimental; Patient outcomes; Receptors; Remission; Survival; T cells; China

Safety and efficacy of allogeneic anti-CD19 chimeric antigen receptor T cells (CAR-T cells) in persons with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) relapsing after an allotransplant remain unclear. Forty-three subjects with B-ALL relapsing post allotransplant received CAR-T cells w...